CBS 2019
CBSMD教育中心
中 文

Other Relevant Articles

Abstract

Recommended Article

Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From the ACC’s Interventional Council and SCAI Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites Incidence of contrast-induced acute kidney injury in a large cohort of all-comers undergoing percutaneous coronary intervention: Comparison of five contrast media Contemporary Antiplatelet Pharmacotherapy in the Management of Acute Coronary Syndromes Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016 Correction of a pathogenic gene mutation in human embryos A Randomized Trial to Assess Regional Left Ventricular Function After Stent Implantation in Chronic Total Occlusion The REVASC Trial A Combination of Allogeneic Stem Cells Promotes Cardiac Regeneration

Original Research2017 Nov 14;70(20):2504-2515.

JOURNAL:J Am Coll Cardiol. Article Link

A Combination of Allogeneic Stem Cells Promotes Cardiac Regeneration

Natsumeda M, Florea V, Hare JM et al. Keywords: allogeneic; cardiac stem cell; ischemic cardiomyopathy; mesenchymal stem cell

ABSTRACT


BACKGROUND - The combination of autologous mesenchymal stem cells (MSCs) and cardiac stem cells(CSCs) synergistically reduces scar size and improves cardiac function in ischemic cardiomyopathy. Whereas allogeneic (allo-)MSCs are immunoevasive, the capacity of CSCs to similarly elude the immune system remains controversial, potentially limiting the success of allogeneic cell combination therapy (ACCT).


OBJECTIVES - This study sought to test the hypothesis that ACCT synergistically promotes cardiac regenerationwithout provoking immunologic reactions.


METHODS - Göttingen swine with experimental ischemic cardiomyopathy were randomized to receive transendocardial injections of allo-MSCs + allo-CSCs (ACCT: 200 million MSCs/1 million CSCs, n = 7), 200 million allo-MSCs (n = 8), 1 million allo-CSCs (n = 4), or placebo (Plasma-Lyte A, n = 6). Swine were assessed by cardiac magnetic resonance imaging and pressure volume catheterization. Immune response was tested by histologic analyses.


RESULTS - Both ACCT and allo-MSCs reduced scar size by -11.1 ± 4.8% (p = 0.012) and -9.5 ± 4.8% (p = 0.047), respectively. Only ACCT, but not MSCs or CSCs, prevented ongoing negative remodeling by offsetting increases in chamber volumes. Importantly, ACCT exerted the greatest effect on systolic function, improving the end-systolic pressure-volume relation (+0.98 ± 0.41 mm Hg/ml; p = 0.016). The ACCT group had more phospho-histone H3+ (a marker of mitosis) cardiomyocytes (p = 0.04), and noncardiomyocytes (p = 0.0002) than did the placebo group in some regions of the heart. Inflammatory sites in ACCT and MSC-treated swine contained immunotolerant CD3+/CD25+/FoxP3+ regulatory T cells (p < 0.0001). Histologic analysis showed absent to low-grade inflammatory infiltrates without cardiomyocyte necrosis.


CONCLUSIONS - ACCT demonstrates synergistic effects to enhance cardiac regeneration and left ventricular functional recovery in a swine model of chronic ischemic cardiomyopathy without adverse immunologic reaction. Clinical translation to humans is warranted.


Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.